Amarin | AMRN - Net Income

Stock Price
14.66
Daily Change
-0.08 -0.54%
Monthly
0.55%
Yearly
79.66%
Q2 Forecast
14.28

Amarin reported $-1.22M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 2.41B 1.52B Dec/2025